Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan.
J Gastroenterol Hepatol. 2010 May;25 Suppl 1:S111-8. doi: 10.1111/j.1440-1746.2010.06223.x.
We examined the effect of lafutidine, a histamine H(2) receptor antagonist with a mucosal protective action mediated by capsaicin-sensitive sensory neurons (CSN), on intestinal lesions produced by loxoprofen administration in rats.
Animals were given loxoprofen (10-100 mg/kg p.o.) and killed 24 h later. Lafutidine (10 and 30 mg/kg), cimetidine (100 mg/kg) or famotidine (30 mg/kg) was given twice p.o. at 0.5 h before and 6 h after loxoprofen. Omeprazole (100 mg/kg) was given p.o. once 0.5 h before. Ampicillin (800 mg/kg) was given p.o. twice at 24 h and 0.5 h before loxoprofen, while 16,16-dimethyl prostaglandin E(2) (dmPGE(2); 0.01 mg/kg) was given i.v. twice at 5 min before and 6 h after.
Loxoprofen dose-dependently produced hemorrhagic lesions in the small intestine, accompanied by invasion of enterobacteria and increased inducible nitric oxide synthase (iNOS) expression as well as myeloperoxidase activity in the mucosa. The ulcerogenic response to loxoprofen (60 mg/kg) was significantly prevented by lafutidine (30 mg/kg), similar to dmPGE(2) and ampicillin, and the effect of lafutidine was totally attenuated by ablation of CSN. Neither cimetidine, famotidine nor omeprazole had a significant effect against these lesions. Lafutidine alone increased mucus secretion and reverted the decreased mucus response to loxoprofen, resulting in suppression of bacterial invasion and iNOS expression. In addition, loxoprofen downregulated Muc2 expression, and this response was totally reversed by lafutidine mediated by CSN.
Lafutidine protects the small intestine against loxoprofen-induced lesions, essentially mediated by the CSN, and this effect may be functionally associated with increased Muc2 expression/mucus secretion, an important factor in the suppression of bacterial invasion.
我们研究了拉呋替丁(一种组胺 H2 受体拮抗剂,其具有通过辣椒素敏感感觉神经元(CSN)介导的黏膜保护作用)对洛索洛芬给药在大鼠中引起的肠道损伤的影响。
动物给予洛索洛芬(10-100mg/kg,po),24 小时后处死。拉呋替丁(10 和 30mg/kg)、西咪替丁(100mg/kg)或法莫替丁(30mg/kg)于洛索洛芬前 0.5 小时和给药后 6 小时 po 给予两次。奥美拉唑(100mg/kg)于洛索洛芬前 0.5 小时 po 给予一次。氨苄西林(800mg/kg)于洛索洛芬前 24 小时和 0.5 小时 po 给予两次,而 16,16-二甲基前列腺素 E2(dmPGE2;0.01mg/kg)则于给药前 5 分钟和给药后 6 小时 iv 给予两次。
洛索洛芬剂量依赖性地在小肠中产生出血性病变,伴有肠细菌入侵和黏膜中诱导型一氧化氮合酶(iNOS)表达以及髓过氧化物酶活性增加。拉呋替丁(30mg/kg)显著预防洛索洛芬(60mg/kg)引起的溃疡形成,类似于 dmPGE2 和氨苄西林,并且 CSN 消融完全减弱了拉呋替丁的作用。西咪替丁、法莫替丁或奥美拉唑对这些病变均无显著作用。拉呋替丁单独增加黏液分泌,并逆转洛索洛芬引起的黏液反应减弱,从而抑制细菌入侵和 iNOS 表达。此外,洛索洛芬下调 Muc2 表达,而拉呋替丁通过 CSN 介导的反应被完全逆转。
拉呋替丁通过 CSN 基本上保护小肠免受洛索洛芬引起的损伤,这种作用可能与增加 Muc2 表达/黏液分泌有关,这是抑制细菌入侵的一个重要因素。